YLT-11

• Description:

  YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Polo-like Kinase (PLK)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ylt-11.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(NC1=NC=CC(C2=CC3=C(C=C2)C(/C=C/C4=CC=C(CN(C)C)C=C4)=NN3)=N1)=O

• Molecular Formula:

  C24H24N6O

• Molecular Weight:

  412.49

• References & Citations:

  [1]Lei Q, et al. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death Dis. 2018 Oct 18;9 (11) :1066.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PLK1; PLK2; PLK3; PLK4